<?xml version='1.0' encoding='utf-8'?>
<document id="30301385"><sentence text="Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase."><entity charOffset="51-61" id="DDI-PubMed.30301385.s1.e0" text="mirabegron" /></sentence><sentence text="This was the first study to construct a physiologically-based pharmacokinetic (PBPK) model for mirabegron which incorporates the overall elimination pathways of metabolism by cytochrome P450 (CYP) 3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7, and butyrylcholinesterase (BChE) and renal excretion"><entity charOffset="95-105" id="DDI-PubMed.30301385.s2.e0" text="mirabegron" /></sentence><sentence text=" The objective was to assess the risk of drug-drug interactions (DDIs) by estimating the contribution of each elimination pathway and simulating the magnitude of the DDIs with UGT2B7 inhibitors" /><sentence text=" A PBPK model for mirabegron was constructed to reproduce the plasma concentration-time curves from a phase 1 study and the magnitude of the DDI with ketoconazole taking into account the overall elimination pathways"><entity charOffset="18-28" id="DDI-PubMed.30301385.s4.e0" text="mirabegron" /><entity charOffset="150-162" id="DDI-PubMed.30301385.s4.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.30301385.s4.e0" e2="DDI-PubMed.30301385.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30301385.s4.e0" e2="DDI-PubMed.30301385.s4.e1" /></sentence><sentence text=" The PBPK model was subsequently verified using data from other DDI studies" /><sentence text=" The constructed PBPK model estimated the contribution for each elimination pathway: 44% and 29% for CYP3A4 and UGT2B7 in the liver, 1" /><sentence text="6% for UGT2B7 in the kidney, 3" /><sentence text="2% for BChE in plasma, and 22% for renal excretion" /><sentence text=" Co-administration of probenecid (an UGT2B7 inhibitor) or fluconazole (an UGT2B7 and CYP3A4 inhibitor) was predicted to increase area under the curve for mirabegron to 115% or 174%, respectively"><entity charOffset="22-32" id="DDI-PubMed.30301385.s9.e0" text="probenecid" /><entity charOffset="58-69" id="DDI-PubMed.30301385.s9.e1" text="fluconazole" /><entity charOffset="154-164" id="DDI-PubMed.30301385.s9.e2" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.30301385.s9.e0" e2="DDI-PubMed.30301385.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30301385.s9.e0" e2="DDI-PubMed.30301385.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30301385.s9.e0" e2="DDI-PubMed.30301385.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30301385.s9.e1" e2="DDI-PubMed.30301385.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30301385.s9.e1" e2="DDI-PubMed.30301385.s9.e2" /></sentence><sentence text=" In conclusion, PBPK modeling and simulation revealed a low DDI risk for mirabegron following co-administration with BChE or UGT2B7 inhibitors" /><sentence text="" /></document>